Stock Analysts

Accuray Retained at Neutral (ARAY) (VAR)

We maintain our Neutral recommendation on Accuray Incorporated ( ARAY ) following its fourth-quarter fiscal 2011 results, which beat the Zacks Consensus Estimates. The company, however, turned into a loss in the quarter as higher revenues were more than masked by hefty charges associated with its acquisition of rival TomoTherapy. […]

Stock Analysts

Williams Aims High Output Capacity (WMB) (WPZ)

Williams Companies ( WMB ) announced plans to expand the production capacity at its Geismar olefins plant. With this move, the facility’s ethylene production capacity will go up by 600 million pounds annually to 1.95 billion pounds. With an 83.3% interest in the Geismar plant, Williams acts as the operator for the facility and expects to incur about $350 million to $400 million for the expansion program in 2012–13 […]

Stock Analysts

Alexion Pharma Upped to Outperform (ALXN)

We are upgrading Alexion Pharmaceuticals ( ALXN ) to Outperform from Neutral following positive data presented for Soliris for an additional indication – generalized myasthenia gravis. Data from the randomized, double-blind, placebo-controlled, cross-over study were presented at the annual scientific session of the Myasthenia Gravis Foundation of America, Inc. […]